<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01688102</url>
  </required_header>
  <id_info>
    <org_study_id>MPO-0787</org_study_id>
    <nct_id>NCT01688102</nct_id>
  </id_info>
  <brief_title>The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile</brief_title>
  <official_title>The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in this study will be randomized to receive either oral vitamin D pills OR
      ultraviolet light treatment. The investigators will compare how these two methods of raising
      vitamin D levels will affect cholesterol levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential subjects will be screened for eligibility, including serum 25(OH)D levels &lt;20ng/ml.
      Eligible subjects will be randomly assigned to receive either: 1) oral vitamin D3, 50,000
      units weekly for 8 weeks or 2) narrow-band UVB radiation, 2 treatments/wk for 8 weeks.
      Duration of treatment will be based on skin type. After 8 weeks, 25(OH)D levels will be
      measured monthly. For participants with levels &lt;35 ng/ml, additional doses of oral vitamin D3
      or UV radiation will be administered.

      A subset of participants from both groups will participate in a skin biopsy cohort, where
      skin biopsies are obtained before and after 8 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LDL Cholesterol Level</measure>
    <time_frame>baseline and 6 months or last observation carried forward (minimum 2 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol</measure>
    <time_frame>baseline and 6 months or last observation carried forward (minimum 2 months)</time_frame>
    <description>Change in Total Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Cholesterol</measure>
    <time_frame>baseline and 6 months or last observation carried forward (minimum 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>baseline 6 months or last observation carried forward (minimum 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C Reactive Protein</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 25(OH)D</measure>
    <time_frame>baseline vs. 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Calcium</measure>
    <time_frame>baseline vs. 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parathyroid Hormone (PTH)</measure>
    <time_frame>baseline vs.6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation Between Change in LDL Cholesterol and Change in Calcium</measure>
    <time_frame>2 months</time_frame>
    <description>The Correlation between change in LDL cholesterol and change in serum calcium</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation Between Change in LDL Cholesterol and Change in PTH</measure>
    <time_frame>2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gene Expression Changes in Peripheral Blood</measure>
    <time_frame>baseline vs. 2 months</time_frame>
    <description>Interferon response genesets (curated by GSEA). Values are presented as the normalized enrichment score, a metric of gene upregulation (when positive) or down-regulation (when negative), normalized for gene set size. This is a useful basis for comparison for direction and degree of change between treatment groups and GSEA genesets.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene Expression Changes in Skin</measure>
    <time_frame>baseline vs. 2 months</time_frame>
    <description>Interferon response genesets (curated by GSEA). Values are presented as the normalized enrichment score, a metric of gene upregulation (when positive) or down-regulation (when negative), normalized for gene set size. This is a useful basis for comparison for direction and degree of change between treatment groups and GSEA genesets.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Oral Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultraviolet Light</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Vitamin D3</intervention_name>
    <description>50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
    <arm_group_label>Oral Vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ultraviolet Light</intervention_name>
    <description>16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
    <arm_group_label>Ultraviolet Light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. Vitamin D 25-OH level &lt; 20 ng/ml

        Exclusion Criteria:

          1. Serum calcium &gt; 10.5 mg/dl

          2. Serum phosphorus &gt; 5.5 mg/dl

          3. Serum parathyroid hormone (PTH) level &lt; 12 pg/ml

          4. LDL cholesterol &gt; 190 mg/dl

          5. History of recent acute infection (within 1 month)

          6. Glomerular filtration rate(GFR) &lt; 60 mL/min

          7. Liver Function tests indicative of liver disease (aspartate aminotransferase (AST) or
             alanine transferase (ALT) &gt; 3x ULN)

          8. Current use of Vitamin D &gt; 400 IU/day

          9. Current use of any statins, fibrates, niacin, or ezetimibe

         10. Current use of any medications affecting sensitivity to UV light

         11. Pregnancy (self-reported)

         12. Intentional UV exposure (e.g. tanning bed use) in the last 2 weeks or planned use
             while participating in the study

         13. history of malignancy not in remission (&gt; 6 months)

         14. History of malignant melanoma

         15. Participation in an investigational drug study within 30 days of the screening visit

         16. Any medical, psychological or social condition that, in the opinion of the
             Investigator, would jeopardize the health or well-being of the participant during any
             study procedures or the integrity of the data.

         17. History of any non-melanoma skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Ponda, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2012</study_first_posted>
  <results_first_submitted>August 2, 2016</results_first_submitted>
  <results_first_submitted_qc>August 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2016</results_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Manish Ponda</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Investigation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Vitamin D3</title>
          <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
        </group>
        <group group_id="P2">
          <title>Ultraviolet Light</title>
          <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Vitamin D3</title>
          <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
        </group>
        <group group_id="B2">
          <title>Ultraviolet Light</title>
          <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="12"/>
                    <measurement group_id="B2" value="39" spread="12"/>
                    <measurement group_id="B3" value="42" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in LDL Cholesterol Level</title>
        <time_frame>baseline and 6 months or last observation carried forward (minimum 2 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol Level</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="18.4"/>
                    <measurement group_id="O2" value="1.4" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol</title>
        <description>Change in Total Cholesterol</description>
        <time_frame>baseline and 6 months or last observation carried forward (minimum 2 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol</title>
          <description>Change in Total Cholesterol</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="22"/>
                    <measurement group_id="O2" value="2.0" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Cholesterol</title>
        <time_frame>baseline and 6 months or last observation carried forward (minimum 2 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="8.1"/>
                    <measurement group_id="O2" value="0.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <time_frame>baseline 6 months or last observation carried forward (minimum 2 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="35.4"/>
                    <measurement group_id="O2" value="1.7" spread="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C Reactive Protein</title>
        <time_frame>baseline and 6 months</time_frame>
        <population>Data analyzed are only for those who completed 6 months of therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C Reactive Protein</title>
          <population>Data analyzed are only for those who completed 6 months of therapy</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="6.87"/>
                    <measurement group_id="O2" value="-.11" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 25(OH)D</title>
        <time_frame>baseline vs. 6 months</time_frame>
        <population>Data only for those who completed 6 months of therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 25(OH)D</title>
          <population>Data only for those who completed 6 months of therapy</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="8.0"/>
                    <measurement group_id="O2" value="15.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Calcium</title>
        <time_frame>baseline vs. 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Calcium</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".09" spread=".35"/>
                    <measurement group_id="O2" value=".07" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Parathyroid Hormone (PTH)</title>
        <time_frame>baseline vs.6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parathyroid Hormone (PTH)</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="19"/>
                    <measurement group_id="O2" value="-9" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation Between Change in LDL Cholesterol and Change in Calcium</title>
        <description>The Correlation between change in LDL cholesterol and change in serum calcium</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Change in LDL Cholesterol and Change in Calcium</title>
          <description>The Correlation between change in LDL cholesterol and change in serum calcium</description>
          <units>Pearson correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24"/>
                    <measurement group_id="O2" value=".16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation Between Change in LDL Cholesterol and Change in PTH</title>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Change in LDL Cholesterol and Change in PTH</title>
          <units>Pearson correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.01"/>
                    <measurement group_id="O2" value=".18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gene Expression Changes in Peripheral Blood</title>
        <description>Interferon response genesets (curated by GSEA). Values are presented as the normalized enrichment score, a metric of gene upregulation (when positive) or down-regulation (when negative), normalized for gene set size. This is a useful basis for comparison for direction and degree of change between treatment groups and GSEA genesets.</description>
        <time_frame>baseline vs. 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Gene Expression Changes in Peripheral Blood</title>
          <description>Interferon response genesets (curated by GSEA). Values are presented as the normalized enrichment score, a metric of gene upregulation (when positive) or down-regulation (when negative), normalized for gene set size. This is a useful basis for comparison for direction and degree of change between treatment groups and GSEA genesets.</description>
          <units>GSEA Normalized Enrichment Score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interferon-alpha response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14"/>
                    <measurement group_id="O2" value="-4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interferon-gamma response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41"/>
                    <measurement group_id="O2" value="-4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gene Expression Changes in Skin</title>
        <description>Interferon response genesets (curated by GSEA). Values are presented as the normalized enrichment score, a metric of gene upregulation (when positive) or down-regulation (when negative), normalized for gene set size. This is a useful basis for comparison for direction and degree of change between treatment groups and GSEA genesets.</description>
        <time_frame>baseline vs. 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vitamin D3</title>
            <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
          </group>
          <group group_id="O2">
            <title>Ultraviolet Light</title>
            <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Gene Expression Changes in Skin</title>
          <description>Interferon response genesets (curated by GSEA). Values are presented as the normalized enrichment score, a metric of gene upregulation (when positive) or down-regulation (when negative), normalized for gene set size. This is a useful basis for comparison for direction and degree of change between treatment groups and GSEA genesets.</description>
          <units>GSEA Normalized Enrichment Score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interferon-alpha response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08"/>
                    <measurement group_id="O2" value="-2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interferon-gamma response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12"/>
                    <measurement group_id="O2" value="-2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Vitamin D3</title>
          <description>Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of oral vitamin D.
Oral Vitamin D3: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed</description>
        </group>
        <group group_id="E2">
          <title>Ultraviolet Light</title>
          <description>Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain &lt;35 ng/ml, subjects will receive additional doses of narrow band UVB.
Ultraviolet Light: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Distress</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Constipation/Hemmorhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin erythema/burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Skin dryness/irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Manish Ponda</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>212-327-7631</phone>
      <email>mponda@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

